Abbott India's Q1 FY24 PAT up at Rs. 290.24 Cr

Abbott India has reported total income of Rs. 1535 crores during the period ended June 30, 2023

SMS Lifesciences India posts Q1 FY24 consolidated loss at Rs. 1.79 Cr

The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr

API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24

Granules India received USFDA approval for the ANDA filed for metoprolol succinate ER tablets

Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma

The inspection closed with zero observations and a classification of No Action Indicated

Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr

The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023

Yashoda Medicity, Indirapuram and Draeger India join hands to establish modular ICU setup

Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes

Dabur India posts Q1 FY24 PAT at Rs. 463.88 Cr

The company has posted net profit of Rs. 463.88 crores for the period ended June 30, 2023

Zydus receives USFDA's final approval for Indomethacin Suppository with competitive generic therapy designation

Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.

Shilpa Medicare lunches pemetrexed injection in India under the brand name VRTU

Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India